Michelle Baker-Jones
Integrative relational therapist / psychedelic therapist
Data updated
Research Footprint
Michelle Baker-Jones appears in 4 tracked papers (2021–2024), most studied alongside Psilocybin, across Anxiety Disorders, Depressive Disorders and Major Depressive Disorder (MDD).
Most-cited paper: Trial of Psilocybin versus Escitalopram for Depression (1334 citations).
Frequent co-authors: Robin Carhart-Harris, David Nutt and David Erritzoe.
Background & Research
Michelle Baker-Jones is an integrative psychotherapeutic counsellor and psychedelic therapist associated with Imperial College London’s Centre for Psychedelic Research. She served as a lead guide on the psilocybin-versus-escitalopram depression trial and has contributed to follow-up and related analyses from that study. Current public profiles also describe her as working in psychedelic therapy and training contexts.
Key Impact
She is a notable therapist and trial guide in Imperial College London’s psilocybin depression studies, including the psilocybin-versus-escitalopram trial.
Collaboration Network
15 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Michelle Baker-Jones is associated with.